Invest – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Thu, 22 Apr 2021 12:00:45 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.4 Microdosing: The Next Revolution in Psychedelics https://mjshareholders.com/microdosing-the-next-revolution-in-psychedelics/ Thu, 22 Apr 2021 12:00:45 +0000 https://www.cannabisfn.com/?p=2918937

Ryan Allway

April 22nd, 2021

App, Exclusive, Psychedelics, Top Story


The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders.

As states liberalize their psychedelics regulations, microdosing has become a popular trend that could offer a variety of mental health benefits. Research on microdosing remains in its infancy, but the combination of placebo-controlled studies and effective delivery systems could translate to a larger-scale trend over the coming years.

Let’s take a closer look at microdosing and how new technologies are making it easier to achieve a consistent result.

What is Microdosing?

Microdosing is the practice of consuming a very low, sub-hallucinogenic dose of a psychedelic substance, such as psilocybin or LSD. While scientific literature contains minimal research, there is plenty of anecdotal evidence to support the practice but the handful of high-quality studies that do exist paint a mixed picture of microdosing efficacy.

In 2018, the Imperial College of London conducted the first placebo-controlled study of microdosing practices. Participants received either a psychedelic or placebo and completed online surveys and cognitive tasks at regular intervals. The results showed improvements in both the psychedelic and placebo groups with no significant differences between them.

Other researchers believe that microdosing may still offer tangible benefits. Maastricht University researchers in the Netherlands conducted their own small-scale placebo-controlled study and found beneficial effects on mood and attention for some participants that couldn’t be explained by the placebo effect. They suggest that timing could be an important factor.

The same researchers from Maastricht University measured brain-derived neurotrophic factor (BNDF)—a protein that affects brain plasticity—and found an increase a few hours after microdosing psychedelics in blood tests. These findings suggest that there is some kind of physiological factor at play with microdosing practices.

 Ensuring the Right Dose

The varying effects of microdosing practices could be the results of varying metabolic rates and drug delivery mechanisms. For instance, capsule-based forms of microdosing involve swallowing a pill that is subject to second-pass metabolism in the liver. Sublingual delivery mechanisms, on the other hand, quickly move to the brain. 

Revive Therapeutics Ltd. (CSE: RVV) is building an intellectual property portfolio around psychedelic drug delivery. After acquiring Psilocin Pharma Corp., the company partnered with Complete Phytochemical Solutions and signed a sponsored research deal with the University of Wisconsin-Madison to develop new delivery methods for psychedelic substances.

The company’s dissolvable oral strips could be especially beneficial for microdosing, delivering between one and 20 milligrams of natural or synthetic psilocybin with rapid onset that bypasses liver metabolism. The company’s other products targeting both psychedelics and cannabinoids include lozenges, gels, creams and transdermal patches. 

While many companies undergo expensive clinical trials, the company’s innovative delivery systems could see a faster path to commercialization as California, Oregon and other states start to legalize psychedelics for personal use. These efforts could open the door to widespread microdosing practices to realize cognitive and other mental health benefits.

Looking Ahead

Investors interested in the psychedelics space may want to consider companies focused on microdosing practices since they could represent a nearer-term path to commercialization. Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) is a prime example with its dissolvable oral strip delivery system for psilocybin microdosing.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
How to Invest in the Rise of Cannabis-Infused Beverages https://mjshareholders.com/how-to-invest-in-the-rise-of-cannabis-infused-beverages/ Wed, 18 Nov 2020 14:01:37 +0000 https://www.cannabisfn.com/?p=2885806

Ryan Allway

November 18th, 2020

App, Exclusive, News, Top Story


The cannabis industry has rapidly transitioned from an obscure counterculture movement to a legal industry that could exceed $27 billion by 2024, according to the MJBiz Daily. In addition to a growing number of states legalizing cannabis, the industry has evolved to provide a growing array of different products, including tinctures, topicals, edibles—and beverages.   

Let’s take a look at the rise of cannabis-infused beverages and how you can invest in Innoviom, Inc.—a pioneer in the space—with as little as $2,500 through the MAZAKALI platform to capitalize on these trends.

Cannabis-Infused Beverages

Cannabis beverages are projected to become a $2.8 billion market by 2025, according to Grand View Research, which represents a blistering 17.8% compound annual growth rate. While the industry is highly fragmented at the moment, Molson Coors projects that cannabis drinks will eventually represent one-third of all cannabis sales as the industry matures.

Click here to receive more information on investing in Innoviom

Several large companies have already begun to position themselves in the space:

  • Heineken launched Hi-Fi Hops—a CBD and THC-infused beverage with zero calories.
  • Molson Coors took a controlling stake in HEXO Inc., a Canadian licensed producer.
  • Anheuser-Busch InBev invested $50 million in a joint venture with Tilray Inc.
  • Constellation Brands acquired a 38% stake in Canopy Growth Corp. for $4 billion.

Many alcohol conglomerates believe that THC-infused beverages could compete with alcohol in the future and seek to position themselves to diversify risk. However, Millennials appear to be equally interested in CBD-infused functional beverages that incorporate natural substances, like adaptogens, probiotics and vitamins, to improve wellness. 

Innoviom Makes Big Progress

Innoviom was founded by executives from Coca-Cola, Pepsi, RedBull and other leading beverage brands to build on these CBD wellness trends and take them to scale. The company’s Wowie™ brand is a hemp-infused beverage that contains 20mg of hemp and a mix of adaptogens designed to promote relaxation.

In combination with Tranquini and its new NaturGeeks brands, the company has been consistently doubling its sales each month through Amazon.com and other online platforms. Management expects to be live in the UK on December 1 and rollout its products in the European Union in January of next year amid its international expansion.

Click here to receive more information on investing in Innoviom

With an established supply chain, manufacturing and distribution network already in place, the company is well on its way to expanding its presence throughout the United States. The company’s move to trademark the name in 120 countries and seek regulatory approval in 30+ countries suggests that further international expansion is also in the cards.

How to Invest in Innoviom

Innoviom has recently announced a $3 million capital raise in order to support its growth. While the company has already closed $1.2 million in funding for this round, interested investors still have an opportunity to participate in the remainder of the financing round over the coming weeks.

Accredited investors can participate in a direct private placement with a minimum investment of $30,000 or invest in MAZAKALI’s Special Investment Vehicle with a minimum investment of just $2,500. For more information, sign up for MAZAKALI’s platform and access the terms.

Click here to receive more information on investing in Innoviom

The Bottom Line

Cannabis beverages have already attracted tremendous interest in both the alcohol and wellness industries. With its unique combination of cannabinoid and non-cannabinoid relaxation beverages, Innoviom is well positioned to benefit from an increase in demand for CBD-infused functional beverages.

For more information, visit the company’s website or request more information today!

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
3 Psychedelische Business Modelle (und was am besten für Investoren ist) https://mjshareholders.com/3-psychedelische-business-modelle-und-was-am-besten-fur-investoren-ist/ Fri, 23 Oct 2020 13:22:40 +0000 https://www.cannabisfn.com/?p=2861596

Ryan Allway

October 23rd, 2020

German, Psychedelics


Die Psychedelikaindustrie hat das Interesse von Pharmaunternehmen geweckt, die nach sichereren und effektiveren Produkten suchen, um ungedeckte medizinische Bedürfnisse im Bereich der psychischen Gesundheit zu befriedigen. Während psychedelische Moleküle vielversprechend sind, verlangen die Pharmahersteller, dass die Moleküle durch wissenschaftliche Techniken verbessert werden, um bestimmte therapeutische Ziele zu erreichen und Toxizitäten zu reduzieren.

Es gibt drei verschiedene Geschäftsmodelle, mit denen psychedelische Unternehmen diese vielversprechenden Medikamente entwickeln. Während die klinische Entwicklung von Medikamentenkandidaten das am häufigsten verwendete Modell ist, konzentrieren sich einige Unternehmen darauf, Moleküle zu entwickeln und dann die Lizenzen an andere Unternehmen zu vergeben. Wieder andere hoffen, den gesamten Prozess der Arzneimittelentwicklung zu umgehen, indem sie sich auf die weniger regulierten Märkte für Konsumgüter verlagern.

Werfen wir einen Blick auf aufkommende psychedelische Geschäftsmodelle und warum MagicMed Industries zu den am besten positionierten Unternehmen in diesem Bereich gehört.

Klicken Sie hier, um mehr über Investitionen in den Bereich der Psychedelika zu erfahren und Aktualisierungen über das Unternehmen zu erhalten

In der klinischen Entwicklung testen typische Pharmaunternehmen im Frühstadium Arzneimittelkandidaten in klinischen Studien mindestens der Phasen I und II. Wenn diese Unternehmen erfolgreich sind, versuchen sie häufig, mit einem größeren Pharmaunternehmen zusammenzuarbeiten, das über die Ressourcen und das Fachwissen verfügt, die erforderlich sind, um klinische Studien der Phase III zu verwalten und das Produkt letztendlich zu vermarkten.

# 1: Klinische Entwicklung

Vorteile

Hohe Margen: Arzneimittel sind in der Regel margenstarke Produkte, da sie Patentschutz genießen und häufig eher von Versicherungsunternehmen als von Einzelpersonen bezahlt werden.

Zugangsbarrieren: Arzneimittel weisen in der Regel hohe Marktzugangsbarrieren auf, da sie in der Regel patentgeschützt sind und die Durchführung klinischer Studien mit hohen Kosten verbunden ist. Insbesondere für die Psychedelika-Branche sind viele Unternehmen nicht in der Lage, einen starken Patentschutz für die von ihnen entwickelten Altmedikamente zu gewährleisten.

Große Märkte: Wenn ungedeckte medizinische Bedürfnisse erheblichen Profit versprechen, können die Marktchancen für Arzneimittel in Milliardenhöhe steigen.

Risiken

Hohe Kosten: Die Durchführung klinischer Studien kostet Millionen von Dollar und dauert Jahre, was häufig zu einer hohen Verdünnung und einem erhöhten Kapitalrisiko für das Unternehmen führt, das die Medikamente entwickelt.

Ausführungsrisiko: Die meisten klinischen Studienprogramme sind letztendlich erfolglos, was bedeutet, dass Pharmaunternehmen, die versuchen, nur einen einzigen Medikamentenkandidaten zu entwickeln, selbst oft erfolglos sind.

# 2: Erzeugung und Vergabe von Lizenzen neuer Moleküle

Einige Biotech-Unternehmen konzentrieren sich auf die Entdeckung und von Lizenzen von Arzneimitteln, um den Arzneimittelentwicklungsprozess für sich und ihre Partner zu beschleunigen. Basierend auf proprietären Methoden und Patenten synthetisieren und validieren diese Unternehmen neue Moleküle. Anschließend vergeben sie die Lizenzen der neuen Moleküle an Partnerunternehmen, die wiederum den Großteil der Entwicklungskosten und -risiken tragen. In der Psychedelikaindustrie werden die vorhandenen, bekannten Moleküle wie Psilocybin, MDMA, LSD und andere als Ausgangspunkt verwendet, von dem aus die neuen Moleküle durch Derivatisierung erzeugt werden.

Vorteile

Hohe Margen: Lizenzbasierte Geschäftsmodelle weisen hohe Margen auf, da nur bescheidene Investitionen für die Erstellung, Patentierung und Validierung erforderlich sind.

Vielfältig und skalierbar: Lizenzbasierte Geschäftsmodelle sind hoch skalierbar und äußerst vielfältig, da sie das Potenzial haben, mit mehreren Molekülen und Unternehmen sowie für verschiedene medizinische Indikationen zusammenzuarbeiten.

Risiken

Marketing: Lizenzbasierte Geschäftsmodelle können schwierig zu implementieren sein, da Lizenznehmer das meiste Ausführungsrisiko übernehmen.

# 3: Konsumgüter

Konsumgüterunternehmen konzentrieren sich darauf, kurzfristige Produkte auf den Markt zu bringen. Ohne die Notwendigkeit behördlicher Genehmigungen öffnen diese Produkte die Tür zu einer kurzfristigeren Kommerzialisierung als Geschäftsmodell für die klinische Entwicklung oder Lizenzierung. Einige Unternehmen entscheiden sich möglicherweise auch für unterstützende Gerichtsbarkeiten außerhalb der USA oder Kanadas.

Vorteile

Sofortige Einnahmen: Das Fehlen regulatorischer Anforderungen führt zu einer schnelleren Markteinführung und vermehrten Möglichkeiten für sofortige Einnahmen.

First-Mover-Vorteil: Frühförderer von Konsumgütern können früher ihre Marken entwickeln, die oft zu Marktführern werden.

Risiken

Geringere Barrieren: Konsumgüter sind normalerweise nicht durch Patente geschützt, was bedeutet, dass Wettbewerber leichter Zugang zum Markt haben.

Niedrigere Margen: Konsumgüter werden aufgrund des fehlenden Patentschutzes in der Regel für viel weniger Geld verkauft als zugelassene, regulierte Arzneimittel.

Kommerzialisierung: Konsumgüter können bei Erfolg schnell zu einer Ware werden, was die Gewinnmargen noch stärker unter Druck setzen kann.

Der einzigartige Ansatz von MagicMed

MagicMed Industries baut ein lizenzbasiertes Geschäftsmodell auf, um Partnern bei der Entwicklung einer breiten Palette von Psychedelika zu helfen, die auf bestimmte Anforderungen zugeschnitten sind.

Die Psybrary ™ des Unternehmens ist eine Bibliothek neuer derivativer Moleküle, die darauf abzielt, Lizenzen an Dritte vergeben zu können, um patentierbare kommerzielle Produkte zu entwickeln. Diese Partner können sich gegenüber Konkurrenten mit vollständig patentierten und validierten Molekülen einen Vorteil verschaffen, um einzigartige pharmakologische Eigenschaften zu bieten, die für auf Ziele der Partner zugeschnitten sind.

Mit dem Ziel, bis Ende des Jahres erste Partner zu gewinnen, könnte MagicMed bereits Ende 2020 oder Anfang 2021 Einnahmen generieren. Weitere Einnahmen aus Meilensteinzahlungen beginnen im Jahr 2022, wenn die Partnerunternehmen klinische Studien durchführen. Das Unternehmen plant, Kunden Forschungskosten und Meilensteinzahlungen sowie langfristige Produktgebühren in Rechnung zu stellen, die den Weg für das Potenzial des blauen Himmels ebnen könnten.

Klicken Sie hier, um mehr über Investitionen in den Bereich Psychedelika zu erfahren und Aktualisierungen über das Unternehmen zu erhalten

Zusätzlich zu den pharmazeutischen Partnern wäre MagicMed gut positioniert, um sich 2022 in den Bereich der Konsumgüter auszuweiten, falls die behördliche Öffnung dies zulässt. Der Schritt könnte einer wachsenden Anzahl von Unternehmen für funktionelle Pilze helfen, patentierte Produkte zu entwickeln, um in einem Markt breit aufgestellt zu sein, der wahrscheinlich einen gewissen Grad an Kommerzialisierung erfahren wird.

Blick in die Zukunft

Es gibt viele verschiedene psychedelische Geschäftsmodelle, aber MagicMed Industries hat eines der vielversprechendsten übernommen – ein Lizenzmodell, das sich sowohl an pharmazeutische als auch an potenzielle Konsumgüterunternehmen richtet. Mit einem erfahrenen Managementteam an der Spitze ist das Unternehmen gut positioniert, um schnell hohe Margenumsätze zu erzielen.

Weitere Informationen finden Sie auf der Website des Unternehmens oder indem Sie die Investorenpräsentation herunterladen.

Haftungsausschluss

Der obige Artikel ist ein gesponserter Inhalt. CannabisFN.com und CFN Media wurden engagiert, um Bewusstsein zu schaffen. Bitte folgen Sie dem folgenden Link, um die vollständige Offenlegung unserer Vergütung einzusehen: http://www.cannabisfn.com/legal-disclaimer/

Dieser Artikel wurde von CFN Enterprises Inc. (OTCQB: CNFN) veröffentlicht, Eigentümer und Betreiber von CFN Media, der branchenweit führenden Agentur und dem Netzwerk für digitale Finanzmedien, die sich der aufstrebenden CBD- und legalen Cannabisindustrie widmen. Weitere Informationen erhalten Sie unter +1 (833) 420-CNFN.

Ryan Allway

Über Ryan Allway

Herr Allway verfügt über mehr als ein Jahrzehnt Erfahrung auf den Finanzmärkten als Privatinvestor und Finanzjournalist. Er ist seit der Gründung der Cannabisindustrie aktiv in ihr tätig und schreibt über öffentliche und private Unternehmen.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Why Locations Matters in Cannabis https://mjshareholders.com/why-locations-matters-in-cannabis/ Mon, 05 Oct 2020 12:00:31 +0000 https://www.cannabisfn.com/?p=2831445

Ryan Allway

October 5th, 2020

App, Exclusive, News, Top Story


The global cannabis industry has projected to be worth $73.6 billion by 2027, according to Grand View Research, which represents a blistering 18.1% compound annual growth rate. While cannabis has historically been grown indoors, outdoor cultivation has become increasingly popular over the past couple of years.

Let’s take a look at the benefits of outdoor cultivation and why the soon-to-go-public Christina Lake Cannabis Corp. (CSE: CLC), which recently began trading on the Canadian Securities Exchange,  is well-positioned to capitalize on these benefits.

Indoor vs. Outdoor Cultivation

Christina Lake Cannabis’ 2020 Outdoor Grow

The debate between indoor and outdoor cultivation has been going on for years.

Indoor cultivation enables companies to fine-tune the environment and grow year-round, but it requires a significant capital investment and has higher ongoing costs. In terms of environmental costs, a single gram of indoor cannabis requires 10 pounds of carbon dioxide due to the significant energy requirements for lights and heat generation.

Outdoor cultivation involves significant lower capital investment—since there’s no building required—and sharply lower ongoing operating costs. These economics enable companies to rapidly scale up to meet demand. While outdoor cultivation uses slightly more water, these environmental costs pale in comparison to the high cost of indoor cultivation.

There are also quality differences between indoor and outdoor cannabis. While indoor cultivation is more tightly controlled, there’s evidence that full-spectrum sunlight improves overall quality compared to artificial lights that have a limited spectrum. The product is closer to nature than indoor products that are more finely tuned to meet certain demands.

Sign up to receive an investor presentation and corporate updates

Investing in the Outdoor Advantage

Canada legalized outdoor cultivation in mid-2018 and several licensed producers began expanding outdoor—but few were built for it from the start.

Christina Lake Cannabis Corp. (CSE: CLC) was built on the idea that outdoor cultivation represents the future of the cannabis industry. With proprietary strains customized for its local outdoor climate, the company planted over 22,500 clones and seedlings in individual pots across 18 acres over the 2020 spring growing season.

Using remote-controlled drones, the company conducts aerial surveillance for quality assurance several times per day. These drones capture real-time video and use sophisticated heat sensors to gauge the health and hydration of each plant. The data is wirelessly transmitted to headquarters where the team can immediately act upon any concerns.

The company has already harvested more than 33,000 pounds or 15,000 kilograms and anticipates a total initial harvest of at least 33,000 pounds or 22,500 kilograms. During the 2021/2022 season, management expects to significantly increase that footprint by 20 to 25 percent by growing on a 99-acre plot that’s directly adjacent to its current facility.

Sign up to receive an investor presentation and corporate updates

A maturing plant at CLC’s outdoor operation

Ideal for Low-Cost Extracts

Outdoor cultivation is uniquely suited for cannabis extracts given the full-spectrum nature of the products and the lack of precise environmental controls.

Christina Lake Cannabis intends to process its ultra-low-cost outdoor cannabis into high-value full-spectrum extracts to maximize revenue and profitability. Using the Vitalis R200 extractor, the company is able to turn cannabis crop into winterized THC oil, as well as isolate terpenes (an increasingly sought-after compound) to create compelling products.

The Vitalis extraction technology also enables the company to expand into supplementary hemp production in the form of toll processing while creating products that are well-positioned to achieve GMP certification, enabling it to sell into European end markets.

After raising C$17 million in funding, the company has ample capital to complete its initial harvest and begin its extraction efforts. The reserves also enable the company to time sales of processed plants based on favorable opportunities in seasonal or industry pricing rather than having to sell products at prevailing market prices.

Sign up to receive an investor presentation and corporate updates

Looking Ahead

Outdoor cultivation has several important advantages over indoor cultivation, including lower cost, efficient expansion and full-spectrum quality. Christina Lake Cannabis (CSE: CLC) intends to capitalize on these characteristics to realize these benefits and become a low-cost producer of both dried cannabis and extracts.

The company recently went public on the Canadian Securities Exchange (CSE) under the ticker symbol “CLC”, creating an opportunity for investors to participate in its growth story. Those interested in exposure to low-cost outdoor cannabis cultivation in Canada may want to take a closer look at the stock as a way to diversify cannabis exposure in their portfolios.

“It was two years ago that our team set out to create a large-scale operation for outdoor cannabis cultivation and extraction,” said CEO Joel Dumaresq. “With our first harvest underway, we look forward to sharing our initial operating results, and building upon that momentum as we seek to establish our reputation as a leader in the Canadian cannabis industry.”

For more information, visit the company’s website or download its investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today https://mjshareholders.com/mydecine-innovations-group-announces-the-official-mindleap-health-mobile-app-launch-in-ios-and-android-stores-today/ Wed, 30 Sep 2020 17:43:53 +0000 https://www.cannabisfn.com/?p=2827904

Ryan Allway

September 30th, 2020

App, News, Top News


DENVER, Colorado, USA – September 30th, 2020 – Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today:

Download on Android

Download on IOS  

Mindleap™ is designed to increase access to mental health services and provide analytics into mental health to improve outcomes starting with goal-setting, mood, emotion, and habit tracking. The platform is free to use for end users and for specialists who want to build a profile after passing the company’s approval process. It is only when an end user purchases services on the platform that Mindleap charges a 9% fee as a percentage of each session.

This is a unique approach that can allow anytime and anywhere access to vetted mental health professionals, and also allows specialists to get approved, set their prices, update their calendar and immediately begin treating new clients. Additionally, users on Mindleap can share their mental health data with their specialist during a secure HD video call to create a more data-driven conversation, as mental health can be very anecdotal and is often hard for people to explain. This convenient and innovative approach coupled with a unique focus on psychedelic integration provides value to both end users and specialists using the software.

The telehealth market is projected to become a $560 billion market by 2027, according to Fortune Business Insights™, which represents a 25.2% compound annual growth rate. The global pandemic has only increased high demand for telehealth services and it’s expected there will be over 1 billion telemedicine sessions by the end of 2020. Mindleap’s innovative technology and business model strive to capture a unique and growing piece of that market starting with psychedelic integration services and expanding into digital mental health programs and other types of mental health services.

Founder and CEO of Mindleap Health, Nikolai Vassev, commented, “It is incredible that a simple idea has become a vibrant company with innovative technology that will soon create a lot of happy customers. Our team carried out the development of an extremely complex system in a short period of time and we are just getting started. Our culture is about continuous improvement and we are already developing our advanced mental health analytics capabilities.”

About Mindleap Health

Mindleap is a telehealth solution that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind. The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs. Mindleap’s proprietary platform is designed by clinical psychologists and neuroscientists to provide professional support and personalized treatment for every user. Our vision is for a world where people can make lasting life changes by having advanced tools and access to expert mental health professionals right from the palm of their hand.

Download for Android

Download for IOS

Watch the Mindleap Platform Overview Video

Apply to become a Specialist on Mindleap

Learn about Mindleap Health

Learn about The Past and Future of Psychedelics as a Medicine

About Mydecine Innovations Group

Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

For further information about Mydecine Innovations Group Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
[email protected]

Corp Communication:
Charles Lee, Investor Relations
[email protected]

Public Relations:
Cynthia Salarizadeh, Public Relations
[email protected]

Mindleap Health Platform Services Disclaimer: Mindleap Services are designed to connect users of our Services with mental health specialists so as to receive assistance and guidance with integrating their prior psychedelic or consciousness-expanding experiences and translating them into positive changes. Our Services are not designed or intended for the integration or translation of a presently occurring psychedelic experience and must not be used for that purpose. Psychedelic substances are legally controlled or prohibited in many jurisdictions, but there are legal means to have a psychedelic or conscious-expanding experience in certain circumstances. You are solely responsible and liable for adequately informing yourself of the Laws of your jurisdiction before using our Services and determining if use of our Services and the receipt of Specialist Services (defined below) is lawful in your jurisdiction. Our Services are meant to be used exclusively in connection with lawful activities and must not be used in connection with illegal substances or illegal activities. Without limiting the previous sentence, you are not permitted to promote, procure, consume, or sell illegal substances through the Services. Do not use psychedelic substances if doing so is unlawful in your jurisdiction. Possession of psychedelic substances in violation of applicable laws can carry significant penalties, including years of incarceration.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
MagicMed Closes Oversubscribed $1.6M Private Placement to Build Out Its Psybrary™ https://mjshareholders.com/magicmed-closes-oversubscribed-1-6m-private-placement-to-build-out-its-psybrary/ Mon, 21 Sep 2020 15:03:43 +0000 https://www.cannabisfn.com/?p=2813856

Ryan Allway

September 21st, 2020

App, Psychedelics, Top Story


The burgeoning psychedelics sector in many ways resembles the cannabis industry of a decade ago. With rising interest in psychedelic medicine, analysts project that the market could grow at a 16.3% compound annual growth rate to $6.85 billion by 2027.

There are a growing number of companies participating in the industry, most of which are pursuing pharmaceutical development paths that will require significant funding and lengthy commercialization timelines—with the exception of a handful of innovative companies.

Let’s take a look at MagicMed Industries’ recent oversubscribed private placement and its plans to use the proceeds to build out its unique psychedelic-derived drug discovery platform.

Strong Interest in Capital Raise

MagicMed Industries recently closed an oversubscribed private placement for gross proceeds of $1,642,880 in conjunction with Mackie Research Capital. Following the transaction, the company has 20,111,520 common shares held by 186 shareholders.

Management intends to use the proceeds, in part, to expand its scientific team and expedite the development of its psychedelic drug discovery platform—the Psybrary™. In developing the library, the company is opening the door to near-term drug development partnerships.

Click here to learn about investing in the psychedelics space and receive corporate updates

CEO Dr. Joseph Tucker on MagicMed’s recent capital raise

In addition to expanding its scientific team, the company hopes to establish a university partnership, file multiple patents and onboard its first partner in 2020. These efforts will continue in 2021 when the company hopes to reach a positive cash flow and ultimately go public.

Powering Psychedelic Drug Discovery

The Psybrary™ is a portfolio of patented derivative molecules that offer an accelerated pathway for partners to develop psychedelics-based medicines. Each derivative molecule is a potential patented drug development candidate for biotech and pharmaceutical partners.

While the compositions of natural and traditional synthetic psychedelic molecules aren’t patentable, the compositions of new derivative molecules that comprise the Psybrary™ are patentable as are the company’s novel manufacturing methods.

The company’s business model is to license these patented molecules to biotech or pharmaceutical companies that would take them through clinical trials. In addition to an upfront licensing fee and milestone payments, the company could generate royalties on commercialized products.

Click here to learn about investing in the psychedelics space and receive corporate updates

Why Investors Should Take Note

The Psybrary™ will initially focus on developing derivatives to psilocybin (magic mushrooms) before expanding into other psychedelic substances, such as MDMA, ketamine, ibogaine, mescaline and ayahuasca. Investors may be interested in a couple of unique features of the business model.

CEO Dr. Joseph Tucker explains the unique opportunity for investors in the psychedelics space

The licensing model could generate high margin, recurring revenue. By avoiding the costs associated with clinical trials, the company maintains low overhead and generates fees by out-licensing intellectual property. Commercial products could generate recurring royalty revenue, too.

With many proprietary molecules and partners, the company’s shareholders could benefit from a highly diversified revenue stream. Pharmaceutical compounds could span multiple conditions and the diversified partnership base serves to derisk revenue source considerations.

Click here to learn about investing in the psychedelics space and receive corporate updates

What’s Next?

MagicMed Industries is well-positioned after having raised over $1.6 million to expand its scientific team and build out its Psybrary™. Investors may want to take a closer look at the stock as it gears up to build partnerships and ultimately commercialize its derivatives portfolio.

The company hopes to reach positive cash flow and go public during the first or second quarter of 2021. In the following year, it hopes to begin receiving multiple milestone payments and diversify into consumer goods categories over time.

For more information, visit the company’s website at www.magicmedindustries.com or download the company’s investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Cannabidiol Phase 1 Clinical Trial Launches, Targeting Inflammatory Heart Condition https://mjshareholders.com/cannabidiol-phase-1-clinical-trial-launches-targeting-inflammatory-heart-condition/ Thu, 17 Sep 2020 17:28:20 +0000 https://www.cannabisfn.com/?p=2812030

Robin Lefferts

September 17th, 2020


Cannabidiol, or CBD, is thought to be beneficial for a wide variety of ailments, ranging from poor sleep to pain to PTSD and beyond. To this point, however, there haven’t been many clinical trials conducted to thoroughly prove or disprove the benefits of CBD. So far, it has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of two rare forms of epilepsy in children, as well as for seizures associated with tuberous sclerosis complex. The approved CBD formulation is Epidiolex®, produced and marketed by GW Pharmaceuticals.

Recently, Cardiol Therapeutics Inc. (TSX: CRDL)(OTCQX: CRTPF) announced the initiation of a Phase 1 clinical study, intended to assess the safety, tolerability, and pharmacokinetics of its own CBD formulation, CardiolRx™. The results of this study will inform Cardiol’s planned Phase 2 international trial of CardiolRx™ for the treatment of acute myocarditis, an inflammatory heart condition. The phase 2 trial is being designed in conjunction with heart experts from leading medical centers in the U.S., Canada, and Germany. Rigorous clinical trials are the only way to drug approval, and Cardiol is hopeful that the abundance of laboratory evidence demonstrating CBD’s anti-inflammatory properties translates into clinical proof of efficacy in treating acute myocarditis.

Acute Myocarditis Caused by Viral Infections, Including COVID-19

Cardiol is looking to follow the path blazed by GW Pharma in utilizing the FDA’s Orphan Drug Designation, a program designed to encourage and fast-track development of drugs for the treatment of rare diseases. Acute myocarditis is thought to affect around 70,000 Americans, fitting nicely under the Orphan Drug cap of 200,000 afflicted citizens, and about double the U.S. patient population represented by GW’s treatment for rare childhood epilepsies (Lennox-Gastaut and Dravet Syndromes).

Acute myocarditis is inflammation of the heart muscle, and it most often results from a viral illness such as Coxsackie B, HIV, adenovirus, and hepatitis C. Currently the disease is not easily treatable, if at all, with supportive management of symptoms through the use of steroids being the most common course of action. It is more common in younger adults and can lead to sudden cardiac death in the most severe cases.

As more information is gathered on the effects of the COVID-19 viral infection, it is becoming apparent that a significant number of COVID-19 patients have markers of heart damage consistent with myocarditis, even among those patients demonstrating mild or no symptoms upon diagnosis. Cardiol, already deep into its CBD/heart research, noticed the connection and filed in May for an international patent covering the use of CBD to improve outcomes for COVID-19 patients. The company plans to initiate a clinical program later this year to investigate the potential benefits of CBD in these cases.

CBD as a Drug

Quality control, standardization, and cost effectiveness are among the hurdles facing drug development companies working with plant-based active ingredients. Deriving pure, consistent active ingredients from various batches of plants is difficult and expensive and can be hard to scale when dealing with most any plant. With cannabis, there is the added layer of the plant’s illegal and psychoactive nature. Supply can be constrained, and contaminants like pesticides are often used in producing the crop at scale.

As with historic plant-based drugs like aspirin (from Willow and other species), and the more recent Taxol (from the Pacific Yew), these issues often lead researchers and companies to develop a synthetic or semi-synthetic version of the active ingredient. Cannabis-derived actives are no different.

Cardiol has created, in conjunction with Dalton Pharma Services, its own pharmaceutical CBD product, CardiolRx™. Produced in cGMP and FDA-approved facilities, CardiolRx™ provides consistency and purity in every batch, without the attendant concerns of plant-derived extracts. Production can be scaled without supply chain and quality issues that can make agricultural production difficult. It is an elegant solution to the issues surrounding cannabis-based drug development.

What’s Ahead

As Cardiol Therapeutics conducts its Phase 1 trial, expected to wrap up later this year, the company has a few other irons in the fire. Cardiol is anticipating the imminent launch of a consumer version of its CBD formulation to the medical cannabis market in Canada. Production (with Dalton Pharma) and distribution (with Medical Cannabis by Shoppers Drug Mart) have already been worked out. The company believes it will be the first CBD formulation available in the market that is free of THC (<10 ppm THC), the psychoactive ingredient of cannabis. This feature could be important for patients who want to steer completely clear of any risk of THC interaction.

Cardiol also has two other clinical pathways to explore. There is the aforementioned COVID-19/heart inflammation/CBD trial, as well as a program to investigate CBD as a treatment for heart failure. The company has chosen to focus on acute myocarditis initially, due in large part to the advantages (time and expense) of potential Orphan Drug development. Keep an eye out in the coming months as Cardiol continues to bring its rigorous scientific approach to the world of cannabinoid drug development.

Interested parties are encouraged to listen to Cardiol Therapeutics’ recent presentation at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference here. Other recent presentations can be found on Cardiol’s website here.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Avatar

About Robin Lefferts


]]>
MagicMed Industries Closes Oversubscribed Private Placement for $1,642,880 with Mackie Research Capital Corporation https://mjshareholders.com/magicmed-industries-closes-oversubscribed-private-placement-for-1642880-with-mackie-research-capital-corporation/ Wed, 02 Sep 2020 13:08:49 +0000 https://www.cannabisfn.com/?p=2808763

Ryan Allway

September 2nd, 2020

Psychedelics, Top News


CALGARY, ABSept. 2, 2020 /CNW/ – MagicMed Industries Inc. (“MagicMed” or the “Company“) is pleased to announce that it has completed, and oversubscribed, its previously announced brokered private placement (the “Offering“) for gross proceeds of $1,642,880.  Pursuant to the Offering, the Company issued 6,571,520 new common shares at a price of $0.25 per common share.  The Company now has 20,111,520 common shares outstanding held by 186 respective shareholders.

The Company intends to use the net proceeds from the Offering for general working capital purposes and to expand its scientific team to expedite and amplify development of the MagicMed PsybraryTM.  While the compositions of natural and traditional synthetic psychedelic molecules are not patentable, the compositions of the new derivative molecules that comprise the MagicMed PsybraryTM are patentable, as are MagicMed’s proprietary methods of manufacturing its new derivative molecules.

“The MagicMed PsybraryTM encompasses the patent portfolio and psychedelic derivative molecules that we offer as an acceleration platform to partner companies in this developing industry,” said MagicMed CEO, Dr. Joseph Tucker.  “Each derivative molecule in the PsybraryTM is a potential patented drug development candidate for our future biotech and pharmaceutical partners.”

The Offering was made by way of private placement in Canada pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued in connection with the Offering are subject to resale restrictions in accordance with applicable securities laws.

Mackie Research Capital Corporation (the “Agent“) acted as agent in connection with the Offering. The Company has paid to the Agent a cash commission equal to 8.0% of the aggregate gross proceeds of the Offering raised from eligible purchasers in addition to a work fee and certain expenses of the Agent.

About MagicMed
MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products. MagicMed’s molecular derivatives library, the PsybraryTM is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the PsybraryTM is on psilocybin, which is expected to be opportunistically expanded to other psychedelics like MDMA, ketamine, Ibogaine, Mescaline, and Ayahuasca. For more information, please visit our website at www.magicmedindustries.com  @MagicMedInd.

Forward Looking Statements 

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and accordingly, actual results and future events could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. All statements other than statements of present or historical fact are forward-looking statements, including statements with respect to MagicMed’s future business plans and partnerships, the anticipated uses of MagicMed’s patents and the development of the PsybraryTM. Forward-looking statements include words or expressions such as “proposed”, “anticipated”, “will”, “subject to”, “near future”, “in the event”, “would”, “expect”, “prepared to” and other similar words or expressions.

Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Some of the risks and other factors could cause results to differ materially from those expressed in the forward-looking statements which include, but are not limited to: the ability of MagicMed to secure patent protection; the ability of MagicMed to enter into partnership agreements or other arrangements; unforeseen challenges in carrying out the business plans of MagicMed; trends in the future use of psilocybin; general business, economic, competitive, political and social uncertainties; the state of capital markets; risks relating to general economic, market and business conditions; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We disclaim any obligation to update or revise these forward-looking statements, except as required by applicable law.

SOURCE MagicMed Industries Inc.

For further information: Joseph Tucker, PhD, CEO, MagicMed Industries Inc., Email: [email protected], Phone: 508-627-0485; Dave Burwell, Investor Relations, VP, The Howard Group, Email: [email protected], Phone: 403-410-7907

Related Links

www.magicmedindustries.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Israel Gives Final Go-Ahead for Cannabis Exports: Here’s Who Could Profit https://mjshareholders.com/israel-gives-final-go-ahead-for-cannabis-exports-heres-who-could-profit/ Fri, 29 May 2020 19:20:09 +0000 https://www.cannabisfn.com/?p=2786033

Ryan Allway

May 29th, 2020

App, Exclusive, News, Top Story


May 29, 2020 — Santa Monica, CA — CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing Israel’s recent approval for cannabis exports and how companies like Isracann Biosciences, Inc. (CSE: IPOT) (OTC: ISCNF) are well-positioned to profit.

Israel gave final approval in mid-May for exports of medical cannabis, paving the way for more than one billion shekels ($273 million) in annual revenue. The country will become one of just three countries that have approved the export of medical cannabis to countries that permit its use—after Canada and the Netherlands— when the law goes into effect on June 13, 2020.

With its favorable climate and expertise in medical and agricultural technologies, Israel could become one of the world’s biggest producers of medical cannabis. iCAN estimates the global market for Israel’s medical cannabis could be as high as $33 billion, while Israeli companies like Syqe Medical have pioneered innovative medical cannabis technologies.

The go-ahead to export medical cannabis could open the door to new investment in the country, while existing Israeli producers, like Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF), could be well-positioned to benefit from near-term export demand.

Click Here To Receive Isracann’s Investor Presentation 

Let’s take a look at who stands to profit from the recent export decision and how investors can position themselves to capitalize on the developments.

Who Stands to Profit?

There are more than ten farms and five factories in Israel that meet the Health Ministry’s standards for medical cannabis exports, and several of them have already reached agreements to sell cannabis to Europe or Canada when licenses become available.

Isracann Biosciences Inc. (CSE: IPOT) (OTCQB: ISCNF) is Israel’s first pure-play cannabis firm wholly focused on becoming the nation’s premier, low-cost cannabis producer. The company has a joint venture agreement in place with a built 55,000 sq. ft. farm that’s expandable to 110,000 sq. ft. in the near-term and has access to over two million sq. ft. of private land.

“Our Hefer Valley farm is making great strides,” said Isracann’s VP of Operations, Matt Chatterton in a recent press release. “We engaged a specialist Israeli consultant to advance the certification of farm to EU-GMP standards thereby paving the way for our export distribution. In addition, the related post-harvest export facility is nearing readiness.”

In addition to its production, Isracann entered into a MOU earlier this year to distribute cannabis throughout European end markets. The distributor will import products through the Republic of Malta, subject to compliance and regulations, and is currently preparing a regional processing facility designed to meet EU-GMP standards.

Breath of Life International Ltd. planned to raise C$150 million on the Toronto Stock Exchange (TSE) through a public share offering priced at C$27 to C$32 per share last year, but management shelved plans for an IPO until market conditions improved in October 2019. The company reported $1.1 million in revenue during the first quarter of 2019 from the Israeli market.

Click here to view an exclusive interview with Isracann’s CEO Darryl Jones:

Click Here To Receive Isracann’s Investor Presentation 

Other Israeli cannabis producers that could benefit include:

  • Cronos Group Inc. (TSX: CRON) has a strategic joint venture with Kibbutz Gan Shmuel, a commercial farming community, whereby it plans to build a 45,000 sq. ft. greenhouse in Israel that will help supply the European market.
  • Aura Health Inc. CSE: BUZZ) holds convertible debt that converts to a 54% equity position in HolyCanna, a cultivation and nursery license in Israel. The company also signed a LOI with CannabiSendak to build a high-profile dispensary in Tel Aviv.
  • Namaste Technologies Inc. (TSX-V: N) owns a 10% stake in Cannbit, a licensed cannabis operation in Israel. The company also has a collaboration and supply agreement with the company to purchase medical cannabis.

What’s Next for Israel?

Israel’s move to legalize medical cannabis exports could be transformative for many public and private companies operating in the country. Investors looking for exposure to the space may want to consider Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) as one of the only pure-plays in the space or a handful of other companies that have exposure through joint ventures and investments.

Learn more about Isracann Biosciences by downloading their investor presentation or visiting their website.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
THC BioMed Reports Growing Revenue & Profitability https://mjshareholders.com/thc-biomed-reports-growing-revenue-profitability/ Thu, 23 Apr 2020 03:05:16 +0000 https://www.cannabisfn.com/?p=2770745

Ryan Allway

April 22nd, 2020

App, Exclusive, News, Top Story


Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations.

THC BioMed Intl Ltd. (CSE: THC) recently recorded its second consecutive quarter of profitability along with more than $1 million in revenue. This represents profits of $88,191 for the three months ended January 31, 2020. Investors looking for exposure to the cannabis industry may want to take a closer look at the stock as an alternative to companies with high cash burn rates and losses in operations.

Click Here To Receive Updates on THC BioMed

Growing Revenue & Outlook

THC BioMed generated more than $1 million in revenue during the first two quarters of fiscal year 2020 with an average selling price of $4.20 per gram to medical patients and recreational buyers, including the Ontario Cannabis Store and BCcannabisonline. During the second quarter alone, revenue rose 163% year-over-year to $1,246,625.

“Over the last year, we have completed and started using new grow rooms to increase our output,” said President & CEO John Miller. “Our focus on high-quality, indoor-grown cannabis at reasonable prices has made our cannabis a best seller.”

The company achieved several key operational milestones over the past six months:

Sales of THC Kiss began on April 10, 2020. The cannabis beverage can be purchased by THC BioMed’s medical patients via the company’s online store.
Pure Cannabis Sticks — or filtered, paper cylinder pre-rolls — went into automated production.
A new three-year lease was signed for a property adjacent to the company’s production facility, which will be used to free up space for more production.
Its Cannabis Act license was amended to include the production and sale of cannabis edibles, topicals and extracts, opening the door to new markets.

Management believes that these operational milestones pave the way for revenue growth over the coming quarters. In particular, the launch of Cannabis 3.0 products will expand the company’s addressable market, while the production efficiencies offered by Pure Cannabis Sticks boost bottom line performance.

Click Here To Receive Updates on THC BioMed

Sustainable Profitability

THC BioMed reported net income of $88,191, gross profit before fair value adjustments of $759,959, and adjusted EBITDA of $131,549 during the second quarter, representing its second consecutive quarter of profitability—a rarity among licensed producers that have historically experienced a high cash burn rate.

Second quarter net income was lower than the $688,925 reported during the first quarter on the surface, but gross profit before fair value adjustments and adjusted EBITDA were higher than first quarter levels of $295,480 and $890, respectively. These figures suggest that the actual bottom line performance has improved quarter over quarter.

“We are proud to have achieved our second consecutive profitable quarter,” added Mr. Miller. “Our financial statements for Q2 2020 reflect the improvements we have realized in all key indicators of economic progress.”

It’s worth noting that the average price of $4.20 per gram is lower than the average prices reported for other licensed producers, which makes the profitability even more significant, as margins are lower than the competition. If industry average prices trend lower, the company doesn’t have to cut its prices in order to remain competitive.

Looking Ahead

THC BioMed Intl Ltd. (CSE: THC) is one of the few profitable licensed producers in the industry, giving them an edge over other companies that are reliant on potentially dilutive future fundraising to stay alive.

Click Here To Receive Updates on THC BioMed

Click here to read the full feature: https://bit.ly/2V2r0Se

THC BioMed Contact:
CEO: John Miller
[email protected]
844-842-6337

CFN Media Contact:

President Frank Lane
[email protected]
206-369-7050

About CFN Media
CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis, CBD & Psychedelic industries.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>